Scancell Holdings PLC's (AIM:SCLP, FRA:SCP) Chief executive, Professor Lindy Durrant talks to Proactive London's Katie Pilbeam after announcing the UK's Medicines and Healthcare Products Regulatory Authority has approved the clinical trial application (CTA) for a phase I/II clinical study of Modi-1.
As Durrant explains Modi-1 is the company’s cancer vaccine candidate. Patient enrolment should take place in the second half of this year.
Modi-1 is to be administered to people with triple-negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer.
